Quarterly ResultMay 5, 2026, 07:12 AM
Viridian Therapeutics Q1 Net Loss $(104.9)M; Pipeline Progress
AI Summary
Viridian Therapeutics reported a net loss of $(104.9) million for Q1 2026, an increase from $(86.9) million in Q1 2025, primarily due to higher operating expenses. The company maintains a strong liquidity position with $762.2 million in cash, cash equivalents, and marketable securities as of March 31, 2026. Key pipeline advancements include upcoming data from REVEAL-2 phase 3 trial for elegrobart in Q2 2026 and phase 1 data for VRDN-008 in H2 2026, alongside ongoing regulatory reviews for veligrotug.
Key Highlights
- Net loss for Q1 2026 was $(104.9) million, compared to $(86.9) million in Q1 2025.
- Total revenues for Q1 2026 were $0.141 million, up from $0.072 million in Q1 2025.
- Research and development expenses increased to $77.6 million in Q1 2026 from $76.8 million in Q1 2025.
- Selling, general and administrative expenses rose to $38.7 million in Q1 2026 from $17.1 million in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $762.2 million as of March 31, 2026.
- Net cash used in operating activities was $(119.7) million for Q1 2026.
- REVEAL-2 phase 3 clinical trial data for elegrobart in TED expected in Q2 2026.
- Veligrotug BLA is under Priority Review by the U.S. FDA, and MAA was submitted to EMA in January 2026.